Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ERBB4 R687K |
| Therapy | Dacomitinib |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ERBB4 R687K | Advanced Solid Tumor | sensitive | Dacomitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Vizimpro (dacomitinib) inhibited growth of a transformed cell line expressing ERBB4 R687K in culture (PMID: 36860695). | 36860695 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (36860695) | An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations. | Full reference... |